ClinicalTrials.gg
CompletedNCT00005106Updated Jun 24, 2005

A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients

A Phase 4 interventional study of Lamivudine/Zidovudine and Abacavir sulfate in HIV Infections, sponsored by Glaxo Wellcome. Completed at 39 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Glaxo Wellcome (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
230
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing lamivudine in HIV Infections — 5 open to participants now, 8 under way, 4 of them phase 3. Lamivudine · HIV Infections.

Enrollment
44th of 126
230 · median 154
Started
1999
with 8 others
Phase 4
29 of 132
3 open now
Registered
44th of 132
by date
Lead sponsor
12 of 132
Glaxo Wellcome

Among the 132 studies testing lamivudine in HIV Infections, this one is the 44th largest by enrollment of the 126 interventional ones that give a count, is one of 9 that started in 1999, is one of 29 in phase 4, and was the 44th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

5 of the 132 studies testing lamivudine in HIV Infections are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About lamivudine

Lamivudine: first FDA approval 1995 (EPIVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing lamivudine in HIV Infections, or all of them as a file.
02

Study summary

The purpose of this study is to look at the effects of different anti-HIV drug combinations on body fat changes in HIV-positive patients who have never received anti-HIV therapy before.

Read the detailed description

Patients are randomized to receive stavudine plus lamivudine plus nelfinavir, Combivir (zidovudine plus lamivudine) plus nelfinavir, or Combivir plus abacavir. Patients are stratified into 2 groups based on their screening plasma HIV-1 RNA: (1) greater than 1,000 up to 100,000 copies/ml or (2) greater than 100,000 up to 200,000 copies/ml. Measurements and evaluations for assessment of body fat composition, virologic and immunologic outcomes, markers of alterations in carbohydrate and lipid metabolism, and safety are performed at Baseline, Weeks 4, 8, 16, 24, and every 12 weeks thereafter until Week 96 or withdrawal. In addition, health-related quality of life and health care resource utilization data are collected at specified treatment visits.

03

Conditions studied

  • HIV Infections

Keywords

  • Drug Therapy, Combination
  • Zidovudine
  • Stavudine
  • HIV Protease Inhibitors
  • Lamivudine
  • Nelfinavir
  • Reverse Transcriptase Inhibitors
  • Anti-HIV Agents
  • Adipose Tissue
  • Lipodystrophy
  • abacavir
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be eligible for this study if they:

  • Are at least 18 years old.
  • Are -positive.
  • Have a greater than 50 cells/mm3.
  • Have a viral load greater than 1,000 copies/ml but less than 200,000 copies/ml.
  • Have never received anti-HIV medications before. (However, less than 1 week of therapy with lamivudine or a protease inhibitor and less than 4 weeks of therapy with other nucleoside reverse transcriptase inhibitors [NRTIs] is allowed. No therapy with nonnucleoside reverse transcriptase inhibitors [NNRTIs] is allowed.)
  • Cannot bear children or agree to use effective methods of during the study. Hormonal methods of birth control (such as birth control pills) are not considered effective for this study.

Exclusion criteria

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Have an active AIDS-defining opportunistic infection or disease that, in the doctor's opinion, would make them unable to participate.
  • Are unable, in the opinion of the doctor, to follow the dosing schedule and follow-up visit schedule.
  • Have a substance abuse problem that would interfere with taking the medications correctly or attending the clinic visits.
  • Are enrolled in another study.
  • Cannot take medications by mouth or absorb drugs.
  • Have hepatitis.
  • Have a serious medical condition such as diabetes, congestive heart failure, or other heart disease.
  • Need chemotherapy or radiation therapy (except for local treatment of Kaposi's sarcoma).
  • Are taking certain medications.
  • Are pregnant or breast-feeding.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Intervention model
Parallel assignment
Enrollment
230 participants

Interventions

06

Study locations

39 sites
  • Univ of Alabama at Birmingham
    Birmingham, Alabama 352942050, United States
  • Arizona Clinical Research Ctr Inc
    Tucson, Arizona 85712, United States
  • Longbeach Memorial Med Ctr
    Longbeach, California 90806, United States
  • Good Samaritan Hosp
    Los Angeles, California 90004, United States
  • THE Clinic
    Los Angeles, California 90008, United States
  • AIDS Healthcare Foundation
    Los Angeles, California 900276069, United States
  • Maxine Liggins
    Los Angeles, California 90042, United States
  • UCLA Care Ctr
    Los Angeles, California 90095, United States
  • Highland Gen Hosp / San Francisco Gen Hosp
    Oakland, California 946021018, United States
  • San Francisco Gen Hosp
    San Francisco, California 94110, United States
  • Georgetown Univ Med Ctr
    Washington, District of Columbia 20007, United States
  • IDC Research Initiative
    Altamonte Springs, Florida 32701, United States
  • Children's Diagnostic Treatment Ctr
    Fort Lauderdale, Florida 33301, United States
  • Community Health Care
    Fort Lauderdale, Florida 33306, United States
  • Comprehensive Care Center
    Fort Lauderdale, Florida 33316, United States
  • Univ of Miami School of Medicine
    Miami, Florida 33136, United States
  • South Shore Hosp
    Miami, Florida 33139, United States
  • Orange County Health Dept
    Orlando, Florida 32805, United States
  • Immunity Care and Research Inc
    Plantation, Florida 33324, United States
  • Daniel Seekins
    Tampa, Florida 33607, United States
  • Infectious Disease Research Institute
    Tampa, Florida 33614, United States
  • AIDS Research Consortium of Atlanta
    Atlanta, Georgia 30308, United States
  • Ponce de Leon Ctr
    Atlanta, Georgia 30308, United States
  • Philip Brachman
    Atlanta, Georgia 30309, United States
  • Rush Presbyterian - Saint Luke's Med Ctr
    Chicago, Illinois 60612, United States
  • Cook County Hosp
    Chicago, Illinois 60614, United States
  • HIV Outpatient Clinics / LA State Univ Med Ctr
    New Orleans, Louisiana 70112, United States
  • Beth Israel Deaconess Med Ctr
    Boston, Massachusetts 02215, United States
  • Univ of Missouri at Kansas City School of Medicine
    Kansas City, Missouri 64108, United States
  • South Jersey Infectious Diseases Inc
    Somers Point, New Jersey 08244, United States
  • WNC Community Health Services
    Asheville, North Carolina 28806, United States
  • Carolinas Med Ctr
    Charlotte, North Carolina 28232, United States
  • Summa Health System
    Akron, Ohio 44304, United States
  • MCP Hahnemann Univ Hosp
    Philadelphia, Pennsylvania 19102, United States
  • Miriam Hosp
    Providence, Rhode Island 02906, United States
  • Univ of Texas Southwestern Med Ctr
    Dallas, Texas 75235, United States
  • Thomas Street Clinic
    Houston, Texas 77009, United States
  • Univ TX San Antonio Health Science Ctr
    San Antonio, Texas 782847881, United States
  • Hampton Roads Med Specialists
    Hampton, Virginia 23666, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00005106
Lead sponsor
Glaxo Wellcome
First posted
Aug 31, 2001
Start date
Sep 1999
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2000. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lamivudine · Zidovudine · Abacavir · Nelfinavir · Stavudine

Start the discussion